| ［1］ Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma［J］. Endocr Rev, 2014, 35(2): 282-326. DOI: 10.1210/er.2013-1029.
［2］ Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma［J］. Am J Surg Pathol, 1989, 13(3): 202-206.
［3］ Stratakis CA. Adrenal cancer in 2013: time to individualize treatment for adrenocortical cancer?［J］. Nat Rev Endocrinol, 2014, 10(2): 76-78. DOI: 10.1038/nrendo.2013.263.
［4］ 蔡燚, 李汉忠, 张玉石. 肾上腺皮质癌的诊治进展［J］. 中华医学杂志, 2016, 96(16): 13071309. DOI: 10.3760/cma.j.issn.03762491.2016.16.020.
［5］ Urup T, Pawlak WZ, Petersen PM, et al. Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase Ⅱ study［J］. Br J Cancer, 2013, 108(10): 1994-1997. DOI: 10.1038/bjc.2013.229.
［6］ Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma［J］. N Engl J Med, 2007, 356(23): 2372-2380. DOI: 10.1056/NFJMoa063360.
［7］ Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma［J］. N Engl Med, 2012, 366(23): 2189-2197. DOI: 10.1056/NEJMoal1200966.
［8］ Bottini A, Generali D, Brizzi MP, et al. Randomized phase Ⅱ trial of letrozole and letrozole plus lowdose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients［J］. J Clin Oncol, 2006, 24(22): 3623-3628. DOI: 10.1200/JCO.2005.04.5773.
［9］ Cazzaniga ME, Camerini A, Addeo R, et al. Metronomic oral vinorelbine in advanced breast cancer and nonsmallcell lung cancer: current status and future development［J］. Future Oncol, 2016, 12(3): 373-387. DOI: 10.2217/fon.15.306. |
